Helge L Waldum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3897661/publications.pdf

Version: 2024-02-01

53939 87275 7,774 257 47 74 citations g-index h-index papers 262 262 262 6448 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Hypergastrinemia and mortality in gastric adenocarcinoma: a population-based cohort study, the HUNT study. Scandinavian Journal of Gastroenterology, 2022, , 1-8.	0.6	1
2	Serotoninâ€"A Driver of Progressive Heart Valve Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 774573.	1.1	4
3	A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 840-849.	1.2	8
4	Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: A prospective populationâ€based nested caseâ€control study. International Journal of Cancer, 2021, 148, 1879-1886.	2.3	9
5	Gastritis, Gastric Polyps and Gastric Cancer. International Journal of Molecular Sciences, 2021, 22, 6548.	1.8	59
6	Tumor Classification Should Be Based on Biology and Not Consensus: Re-Defining Tumors Based on Biology May Accelerate Progress, An Experience of Gastric Cancer. Cancers, 2021, 13, 3159.	1.7	3
7	Chronic diseases: what about infections of virus and prions <i>via</i> the gut?. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110288.	1.4	O
8	Pharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and females. Scandinavian Journal of Gastroenterology, 2021, 56, 128-136.	0.6	5
9	Time to Classify Tumours of the Stomach and the Kidneys According to Cell of Origin. International Journal of Molecular Sciences, 2021, 22, 13386.	1.8	5
10	Stomach Hormones. , 2020, , 341-359.		0
11	Reflections after 10 years as Editor, including 8 years as Editor-in-Chief in Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology, 2020, 55, 638-639.	0.6	0
12	Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells. Cancers, 2020, 12, 3477.	1.7	13
13	Sa1336 HYPERGASTRINEMIA IS ASSOCIATED WITH PROXIMAL AND INTESTINAL TYPE GASTRIC ADENOCARCINOMA. Gastroenterology, 2020, 158, S-321-S-322.	0.6	0
14	The increase in early-onset gastric carcinomas from 1995 is probably due to the introduction of proton pump inhibitors. Surgery, 2020, 168, 568-569.	1.0	6
15	Correct Identification of Cell of Origin May Explain Many Aspects of Cancer: The Role of Neuroendocrine Cells as Exemplified from the Stomach. International Journal of Molecular Sciences, 2020, 21, 5751.	1.8	7
16	Clinical consequences of controversies in gastric physiology. Scandinavian Journal of Gastroenterology, 2020, 55, 752-758.	0.6	0
17	Gastrin drives gastric cancer due to oxyntic atrophy also after Helicobacter pylori eradication. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093171.	1.4	3
18	Sa1332 GASTRIC CORPUS MUCOSAL HYPERPLASIA AND NEUROENDOCRINE CELL HYPERPASIA, BUT NOT SPASMOLYTIC POLYPEPTICE-EXPRESSING METAPLASIA, IS PREVENTED BY A GASTRIN-BLOCKER IN H+/K+ ATPASE BETA SUBUNIT DEFICIENT MICE. Gastroenterology, 2020, 158, S-319-S-320.	0.6	0

#	Article	IF	CITATIONS
19	Gastric Corpus Mucosal Hyperplasia and Neuroendocrine Cell Hyperplasia, but not Spasmolytic Polypeptide-Expressing Metaplasia, Is Prevented by a Gastrin Receptor Antagonist in H+/K+ATPase Beta Subunit Knockout Mice. International Journal of Molecular Sciences, 2020, 21, 927.	1.8	1
20	Enterochromaffin-Like (ECL) Cells. , 2020, , 265-272.		O
21	Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection. Scandinavian Journal of Gastroenterology, 2019, 54, 1003-1007.	0.6	8
22	Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility. International Journal of Molecular Sciences, 2019, 20, 5203.	1.8	92
23	Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia. Scandinavian Journal of Gastroenterology, 2019, 54, 1118-1123.	0.6	26
24	Sa1208 – Serum Concentration and Pharmacokinetics of Single and Repeated Oral Doses of Esomeprazole and Gastrin Elevation in Healthy Males and Females. Gastroenterology, 2019, 156, S-308.	0.6	2
25	The Enterochromaffin-like [ECL] Cell—Central in Gastric Physiology and Pathology. International Journal of Molecular Sciences, 2019, 20, 2444.	1.8	25
26	The Phylogeny and Biological Function of Gastric Juice—Microbiological Consequences of Removing Gastric Acid. International Journal of Molecular Sciences, 2019, 20, 6031.	1.8	45
27	Role of Autoimmune Gastritis in Gastric Cancer. Clinical and Translational Gastroenterology, 2019, 10, e00080.	1.3	9
28	Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells. Hormones and Cancer, 2018, 9, 40-54.	4.9	23
29	Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man. Gut, 2018, 67, 199.2-200.	6.1	21
30	Types of Gastric Carcinomas. International Journal of Molecular Sciences, 2018, 19, 4109.	1.8	78
31	Proton pump inhibitors (PPIs) may cause gastric cancer – clinical consequences. Scandinavian Journal of Gastroenterology, 2018, 53, 639-642.	0.6	33
32	Editorial: proton pump inhibitors (<scp>PPI</scp> s) and primary liver cancer. Alimentary Pharmacology and Therapeutics, 2018, 48, 380-381.	1.9	0
33	Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481877505.	1.4	14
34	Expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma. Apmis, 2017, 125, 213-222.	0.9	15
35	Chronic cholestatic liver diseases. Scandinavian Journal of Gastroenterology, 2017, 52, 788-788.	0.6	0
36	Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation. Journal of Histochemistry and Cytochemistry, 2017, 65, 687-703.	1.3	32

3

#	Article	IF	CITATIONS
37	Netazepide, a gastrin/cholecystokininâ€2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. British Journal of Clinical Pharmacology, 2017, 83, 466-475.	1.1	49
38	Gastrin and Gastric Cancer. Frontiers in Endocrinology, 2017, 8, 1.	1.5	138
39	The cytoprotective protein clusterin is overexpressed in hypergastrinemic rodent models of oxyntic preneoplasia and promotes gastric cancer cell survival. PLoS ONE, 2017, 12, e0184514.	1.1	9
40	ECLâ€cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H ⁺ K ⁺ ATPase alpha subunit. Apmis, 2016, 124, 561-566.	0.9	30
41	Classification of Epithelial Malignant Tumors—the Differentiation Between Adenocarcinomas and Neuroendocrine Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 309-312.	0.6	8
42	<i>Helicobacter pylori</i> and gastric acid: an intimate and reciprocal relationship. Therapeutic Advances in Gastroenterology, 2016, 9, 836-844.	1.4	58
43	340 Signet Ring Cell Carcinomas Identified As a New Molecular Subtype of Gastric Cancer. Gastroenterology, 2016, 150, S80.	0.6	0
44	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1026.	4.5	2
45	Follow-up of patients with ECL cell-derived tumours. Scandinavian Journal of Gastroenterology, 2016, 51, 1398-1405.	0.6	8
46	Gastrin Secretion After Bariatric Surgeryâ€"Response to a Protein-Rich Mixed Meal Following Roux-En-Y Gastric Bypass and Sleeve Gastrectomy: a Pilot Study in Normoglycemic Women. Obesity Surgery, 2016, 26, 1448-1456.	1.1	21
47	Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?. Scandinavian Journal of Gastroenterology, 2016, 51, 767-773.	0.6	18
48	Protonpumpehemmere og magekreft. Tidsskrift for Den Norske Laegeforening, 2016, 136, 13-14.	0.2	1
49	Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival. Apmis, 2015, 123, 509-514.	0.9	32
50	Upper gastrointestinal physiology and diseases. Scandinavian Journal of Gastroenterology, 2015, 50, 649-656.	0.6	12
51	5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scandinavian Journal of Gastroenterology, 2015, 50, 933-941.	0.6	54
52	Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia. Alimentary Pharmacology and Therapeutics, 2015, 42, 389-389.	1.9	2
53	Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach. Digestive Diseases and Sciences, 2015, 60, 1522-1527.	1.1	41
54	Re: E-sigaretter – til skade eller nytte?. Tidsskrift for Den Norske Laegeforening, 2015, 135, 1222-1223.	0.2	0

#	Article	IF	Citations
55	Re: E-sigaretter – til skade eller nytte?. Tidsskrift for Den Norske Laegeforening, 2015, 135, 1338-1338.	0.2	O
56	The gastric mucosa 25 years after proximal gastric vagotomy. Scandinavian Journal of Gastroenterology, 2014, 49, 1173-1180.	0.6	4
57	The normal neuroendocrine cells of the upper gastrointestinal tract lack E-cadherin. Scandinavian Journal of Gastroenterology, 2014, 49, 974-978.	0.6	15
58	Venous plasma serotonin is not a proper biomarker for pulmonary arterial hypertension. Scandinavian Cardiovascular Journal, 2014, 48, 106-110.	0.4	3
59	Involvement of NF- <i>κ</i> B/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis Mice. International Journal of Inflammation, 2014, 2014, 1-7.	0.9	23
60	The regulation of gastric acid secretion – clinical perspectives. Acta Physiologica, 2014, 210, 239-256.	1.8	57
61	The PAS positive material in gastric cancer cells of signet ring type is not mucin. Experimental and Molecular Pathology, 2014, 96, 274-278.	0.9	23
62	Sa1873 Serum Gastrin in Relation to Localization and Histological Sub-Classification of Non-Cardia Adenocarcinomas in the Stomach. Gastroenterology, 2014, 146, S-317-S-318.	0.6	0
63	Enhanced Expression of CXCL10 in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 265-274.	0.9	62
64	Sa2014 Unilateral Truncal Vagotomy Reduces Stomach Weight, Oxyntic Mucosal Thickness and Neuroendocrine Cell Density but Does Not Prevent Gastric Carcinoma Development in Hypergastrinemic Female Japanese Cotton Rats. Gastroenterology, 2013, 144, S-359-S-360.	0.6	0
65	The Gastrin Receptor Antagonist Netazepide (<scp>YF</scp> 476) Prevents Oxyntic Mucosal Inflammation Induced by <i>Helicobacter Pylori</i> Infection in Mongolian Gerbils. Helicobacter, 2013, 18, 397-405.	1.6	13
66	Editorial. Scandinavian Journal of Gastroenterology, 2013, 48, 3-3.	0.6	0
67	Tu1613 Evaluation of Mucin and Neuroendocrine Expression in Diffuse Gastric Cancer With Signet Ring Cell Morphology. Gastroenterology, 2013, 144, S-806.	0.6	2
68	Tu1089 Somatostatin and the Slow-Growing Nature of Small Intestinal Neuroendocrine Tumors. Gastroenterology, 2013, 144, S-758-S-759.	0.6	0
69	The effects of unilateral truncal vagotomy on gastric carcinogenesis in hypergastrinemic Japanese female cotton rats. Regulatory Peptides, 2013, 184, 62-67.	1.9	3
70	Serotonin in blood: Assessment of its origin by concomitant determination of \hat{l}^2 -thromboglobulin (platelets) and chromogranin A (enterochromaffin cells). Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 148-153.	0.6	6
71	The Distressing Overuse of Gastric Acid Inhibitors. Digestive Diseases and Sciences, 2013, 58, 600-601.	1.1	2
72	Symptomatic Primary (AL) Amyloidosis of the Stomach and Duodenum. Case Reports in Gastrointestinal Medicine, 2013, 2013, 1-3.	0.2	9

#	Article	IF	Citations
73	Gastric acid inhibitors may prevent/heal oxyntic lesions by reducing blood demand. Gut, 2013, 62, 184.2-184.	6.1	O
74	In Situ Hybridization in Human and Rodent Tissue by the Use of a New and Simplified Method. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 185-189.	0.6	17
75	Development of diffuse carcinomas in the gastric corpus in patients with rugal hyperplastic gastritis. International Journal of Cancer, 2013, 133, 2260-2260.	2.3	O
76	Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clinical and Experimental Immunology, 2013, 173, 502-511.	1.1	44
77	Whole Genome Gene Expression Meta-Analysis of Inflammatory Bowel Disease Colon Mucosa Demonstrates Lack of Major Differences between Crohn's Disease and Ulcerative Colitis. PLoS ONE, 2013, 8, e56818.	1.1	111
78	Immunohistochemical evidence for an impairment of autophagy in tumorigenesis of gastric carcinoids and adenocarcinomas in rodent models and patients. Histology and Histopathology, 2013, 28, 531-42.	0.5	16
79	Gastric Carcinomas Localized to the Cardia. Gastroenterology Research and Practice, 2012, 2012, 1-6.	0.7	2
80	Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scandinavian Journal of Gastroenterology, 2012, 47, 64-67.	0.6	70
81	Induction of Lipocalin-2 in Colonic Epithelial Cells in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2012, 18, S109-S110.	0.9	0
82	Dissecting the IBD Transcriptome. Inflammatory Bowel Diseases, 2012, 18, S61-S62.	0.9	0
83	Gastric carcinoids after longâ€ŧerm use of a proton pump inhibitor. Alimentary Pharmacology and Therapeutics, 2012, 36, 644-649.	1.9	104
84	Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2012, 47, 649-657.	0.6	16
85	Mo1560 Impaired Autophagy in Gastric Carcinoids and Adenocarcinoma of Both Rodent Models and Patients. Gastroenterology, 2012, 142, S-628.	0.6	1
86	Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Alimentary Pharmacology and Therapeutics, 2012, 36, 1067-1075.	1.9	94
87	57 Treatment of Gastric Carcinoids Type 1 With the Gastrin Receptor Antagonist YF476 Results in Regression of Tumours and Normalisation of Serum Chromogranin A. Gastroenterology, 2012, 142, S-15.	0.6	1
88	Withdrawing PPI Therapy: Response to Metz et al American Journal of Gastroenterology, 2012, 107, 325-326.	0.2	1
89	Decreased bone mineral density and reduced bone quality in H ⁺ /K ⁺ ATPase betaâ€subunit deficient mice. Journal of Cellular Biochemistry, 2012, 113, 141-147.	1.2	21
90	Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scandinavian Journal of Gastroenterology, 2011, 46, 1418-1422.	0.6	12

#	Article	IF	Citations
91	Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation. Diabetes, Obesity and Metabolism, 2011, 13, 551-558.	2.2	76
92	Animal Models to Study the Role of Long-Term Hypergastrinemia in Gastric Carcinogenesis. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-6.	3.0	15
93	Parietal cell activation by arborization of ECL cell cytoplasmic projections is likely the mechanism for histamine induced secretion of hydrochloric acid. Scandinavian Journal of Gastroenterology, 2011, 46, 531-537.	0.6	17
94	Activation of REG family proteins in colitis. Scandinavian Journal of Gastroenterology, 2011, 46, 1316-1323.	0.6	42
95	Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scandinavian Journal of Gastroenterology, 2011, 46, 456-463.	0.6	50
96	Neuroendocrine Cells in Diffuse Gastric Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 62-68.	0.6	9
97	A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumor Biology, 2010, 31, 373-380.	0.8	23
98	PPI-induced hypergastrinaemia and Barrett's mucosa: the fog thickens. Gut, 2010, 59, 1157-1158.	6.1	1
99	Long-term gastric changes in achlorhydric H+/K+-ATPase beta subunit deficient mice. Scandinavian Journal of Gastroenterology, 2010, 45, 1042-1047.	0.6	11
100	Oral proton-pump inhibitors and step-down therapy for nonulcer dyspepsia: is this the right approach?. Therapeutic Advances in Gastroenterology, 2010, 3, 73-76.	1.4	2
101	Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scandinavian Journal of Gastroenterology, 2010, 45, 389-394.	0.6	61
102	This month in Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology, 2010, 45, 772-774.	0.6	1
103	Effect of antrectomy in hypergastrinaemic female Japanese cotton rats. Scandinavian Journal of Gastroenterology, 2009, 44, 32-39.	0.6	2
104	495 WITHDRAWN. Gastroenterology, 2009, 136, A-80.	0.6	0
105	Interactions between gastric acid secretagogues and the localization of the gastrin receptor. Scandinavian Journal of Gastroenterology, 2009, 44, 390-393.	0.6	11
106	Neuroendocrine tumor epidemiology. Cancer, 2008, 113, 2655-2664.	2.0	464
107	Gastric Neuroendocrine Carcinoma Associated with Atrophic Gastritis in the Norwegian Lundehund. Journal of Comparative Pathology, 2008, 139, 194-201.	0.1	36
108	Classification of tumours. Journal of Experimental and Clinical Cancer Research, 2008, 27, 70.	3.5	31

#	Article	IF	CITATIONS
109	The Effect of Terguride in Carbon Tetrachloride–Induced Liver Fibrosis in Rat. Experimental Biology and Medicine, 2008, 233, 1385-1388.	1.1	4
110	Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scandinavian Journal of Gastroenterology, 2008, 43, 20-24.	0.6	51
111	Ghrelin Immunoreactive Cells in Gastric Endocrine Tumors and Their Relation to Plasma Ghrelin Concentration. Journal of Clinical Gastroenterology, 2008, 42, 381-388.	1.1	29
112	Changes in gene expression of gastric mucosa during therapeutic acid inhibition. European Journal of Gastroenterology and Hepatology, 2008, 20, 613-623.	0.8	12
113	pH 4.0. Scandinavian Journal of Gastroenterology, 2007, 42, 297-298.	0.6	3
114	Long-term serotonin effects in the rat are prevented by terguride. Regulatory Peptides, 2007, 143, 39-46.	1.9	38
115	Octreotide induces apoptosis in the oxyntic mucosa. Molecular and Cellular Endocrinology, 2007, 264, 188-196.	1.6	7
116	Long Slender Cytoplasmic Extensions: A Common Feature of Neuroendocrine Cells?. Journal of Neuroendocrinology, 2007, 19, 739-742.	1.2	10
117	Expression of neuroendocrine markers in non-small cell lung cancer Apmis, 2007, 115, 152-163.	0.9	24
118	Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. World Journal of Gastroenterology, 2007, 13, 493.	1.4	42
119	A new method for visualization of gut mucosal cells, describing the enterochromaffin cell in the rat gastrointestinal tract. Scandinavian Journal of Gastroenterology, 2006, 41, 390-395.	0.6	32
120	Gene expression analysis and clinical diagnosis. Clinica Chimica Acta, 2006, 363, 157-164.	0.5	34
121	Tobacco and Cancer in the Digestive Tract. , 2006, , 229-236.		0
122	Achlorhydria, Parietal Cell Hyperplasia, and Multiple Gastric Carcinoids: A New Disorder?. American Journal of Surgical Pathology, 2006, 30, 919.	2.1	3
123	ECL cell histamine mobilization and parietal cell stimulation in the rat stomach studied by microdialysis and electron microscopy. Acta Physiologica, 2006, 186, 37-43.	1.8	12
124	Chronic inhalation of carbon monoxide: Effects on the respiratory and cardiovascular system at doses corresponding to tobacco smoking. Toxicology, 2006, 228, 280-290.	2.0	33
125	Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. Journal of Cellular Biochemistry, 2006, 97, 1283-1291.	1.2	61
126	Serotonin and fluoxetine modulate bone cell function in vitro. Journal of Cellular Biochemistry, 2006, 98, 139-151.	1.2	141

#	Article	IF	Citations
127	Signet Ring Cells in Gastric Carcinomas Are Derived from Neuroendocrine Cells. Journal of Histochemistry and Cytochemistry, 2006, 54, 615-621.	1.3	69
128	Molecular characterization of rat gastric mucosal response to potent acid inhibition. Physiological Genomics, 2005, 22, 24-32.	1.0	22
129	Idiopathic gastric acid hypersecretion. European Journal of Gastroenterology and Hepatology, 2005, 17, 1433.	0.8	0
130	Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Alimentary Pharmacology and Therapeutics, 2005, 21, 149-154.	1.9	106
131	Gastric Juice: A Barrier Against Infectious Diseases. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 94-102.	1.2	264
132	Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats. Apmis, 2005, 113, 436-449.	0.9	18
133	Ultrastructure and chromogranin A immunogold labelling of ECL cell carcinoids. Apmis, 2005, 113, 506-512.	0.9	17
134	Antiulcer Drugs and Gastric Cancer. Digestive Diseases and Sciences, 2005, 50, S39-S44.	1.1	38
135	Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-α. American Journal of Physiology - Renal Physiology, 2005, 289, G1052-G1060.	1.6	6
136	Long-Term Serotonin Administration Induces Heart Valve Disease in Rats. Circulation, 2005, 111, 1517-1522.	1.6	229
137	One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scandinavian Journal of Gastroenterology, 2005, 40, 1269-1274.	0.6	27
138	Hypergastrinaemia in patients infected with Helicobacter pylori treated with proton pump inhibitors. Gut, 2005, 54, 566.	6.1	13
139	ECL-Cell Derived Gastric Cancer in Male Cotton Rats Dosed with the H2-Blocker Loxtidine. Cancer Research, 2004, 64, 3687-3693.	0.4	29
140	Spontaneous enterochromaffin-like cell carcinomas in cotton rats (Sigmodon hispidus) are prevented by a somatostatin analogue Endocrine-Related Cancer, 2004, 11, 149-160.	1.6	11
141	Hypergastrinaemia induced by partial corpectomy results in development of enterochromaffinâ€ike cell carcinoma in male Japanese cotton rats. Scandinavian Journal of Gastroenterology, 2004, 39, 919-926.	0.6	9
142	Rebound Hypersecretion after Inhibition of Gastric Acid Secretion. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 202-208.	1.2	26
143	Hypergastrinemia in animals and man: causes and consequences. Scandinavian Journal of Gastroenterology, 2004, 39, 505-509.	0.6	29
144	Clinical significance of elevated serum chromogranin A levels. Scandinavian Journal of Gastroenterology, 2004, 39, 969-973.	0.6	44

#	Article	IF	Citations
145	Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian Journal of Gastroenterology, 2004, 39, 621-628.	0.6	72
146	Gene expression based classification of gastric carcinoma. Cancer Letters, 2004, 210, 227-237.	3.2	26
147	Cytotoxicity of streptozotocin on neuroendocrine cells of the pancreas and the gut. Digestive Diseases and Sciences, 2003, 48, 906-910.	1.1	45
148	Reg protein in gastric cancer tumour cells. FEBS Letters, 2003, 553, 464-465.	1.3	4
149	Chronic Helicobacter pylori infection results in gastric hypoacidity and hypergastrinemia in wild-type mice but vagally induced hypersecretion in gastrin-deficient mice. Regulatory Peptides, 2003, 115, 161-170.	1.9	16
150	Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis, 2003, 24, 1887-1896.	1.3	54
151	Liver gene expression in rats in response to the peroxisome proliferator-activated receptor- $\hat{l}\pm$ agonist ciprofibrate. Physiological Genomics, 2003, 15, 9-19.	1.0	38
152	Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opinion on Drug Safety, 2002, 1, 29-38.	1.0	55
153	Gastric Acidity Protects Mice Against Prion Infection?. Scandinavian Journal of Gastroenterology, 2002, 37, 497-500.	0.6	33
154	Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. Apmis, 2002, 110, 132-139.	0.9	77
155	Neuroendocrine differentiation in carcinoma of the breast. Tyramide signal amplification discloses chromogranin A-positive tumour cells in more breast tumours than previously realized. Apmis, 2002, 110, 658-664.	0.9	17
156	The Cellular Localization of the Cholecystokinin 2 (Gastrin) Receptor in the Stomach. Basic and Clinical Pharmacology and Toxicology, 2002, 91, 359-362.	0.0	17
157	Glycine-extended gastrin-17 stimulates acid secretion only via CCK-2 receptor-induced histamine release in the totally isolated vascularly perfused rat stomach. Acta Physiologica Scandinavica, 2002, 174, 125-130.	2.3	11
158	Long-term Omeprazole Treatment Suppresses Body Weight Gain and Bone Mineralization in Young Male Rats. Scandinavian Journal of Gastroenterology, 2001, 36, 1011-1015.	0.6	54
159	PACAP stimulates gastric acid secretion in the rat by inducing histamine release. American Journal of Physiology - Renal Physiology, 2001, 281, G997-G1003.	1.6	35
160	Neuroendocrine Differentiation in Bronchial Carcinomas of Classic Squamous-Cell Type. Applied Immunohistochemistry and Molecular Morphology, 2001, 9, 9-13.	0.6	0
161	Neuroendocrine Differentiation in Bronchial Carcinomas of Classic Squamous-Cell Type. Applied Immunohistochemistry & Molecular Morphology, 2001, 9, 9-13.	2.0	7
162	Reply - on gastric polyps, proton pump inhibitors and long-term risks. Alimentary Pharmacology and Therapeutics, 2001, 15, 559-560.	1.9	2

#	Article	IF	Citations
163	Serum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion. European Journal of Clinical Investigation, 2001, 31, 741-743.	1.7	9
164	Letter to the editor. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 439, 215-216.	1.4	5
165	Hypergastrinemia as a Cause of Chromogranin A Increase in Blood in Patients Suspected to Have Neuroendocrine Tumor. Digestion, 2001, 64, 71-74.	1.2	11
166	The CCK-2 Receptor is Located on the ECL Cell, But Not on the Parietal Cell. Scandinavian Journal of Gastroenterology, 2001, 36, 1128-1133.	0.6	75
167	Neuroendocrine differentiation in bronchial carcinomas of classic squamous-cell type: an immunohistochemical study of 29 cases applying the tyramide signal amplification technique. Applied Immunohistochemistry and Molecular Morphology, 2001, 9, 9-13.	0.6	3
168	Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: A study by elutriation centrifugation. Acta Physiologica Scandinavica, 2000, 169, 29-37.	2.3	60
169	Oxyntic lesions may be provoked in the rat both by the process of acid secretion and also by gastric acidity. Alimentary Pharmacology and Therapeutics, 2000, 14, 135-141.	1.9	7
170	Personal review: is profound acid inhibition safe?. Alimentary Pharmacology and Therapeutics, 2000, 14, 15-22.	1.9	40
171	Safety of proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 2000, 14, 1537-1538.	1.9	12
172	Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. The Histochemical Journal, 2000, 32, 551-556.	0.6	61
173	Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia. Journal of Molecular Endocrinology, 2000, 25, 109-119.	1.1	21
174	Spontaneous ECLomas in cotton rats (Sigmodon hispidus): tumours occurring in hypoacidic/hypergastrinaemic animals with normal parietal cells. Carcinogenesis, 2000, 21, 23-27.	1.3	25
175	Chromogranin A (CGA) and the Enterochromaffin-Like (ECL) Cell. , 2000, 482, 361-367.		10
176	Vagal stimulation augments maximal (penta) gastrinâ€stimulated acid secretion in humans. Acta Physiologica Scandinavica, 1999, 165, 277-281.	2.3	8
177	Chronic Carbon Monoxide Exposure ⟨i>in vivo⟨/i> Induces Myocardial Endothelinâ€1 Expression and Hypertrophy in Rat. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 192-197.	0.0	25
178	Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomasâ€). Apmis, 1999, 107, 1085-1092.	0.9	69
179	Lack of effect of transdermal nicotine on 3 cases of primary sclerosing cholangitis. Digestive Diseases and Sciences, 1999, 44, 2484-2484.	1.1	0
180	Re. Editorial entitled ?The origin of gut and pancreatic neuroendocrine (APUD) cells?the last word??., 1999, 188, 113-114.		9

#	Article	IF	CITATIONS
181	Neuroendocrine (ECL cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Laboratory Animal Science, 1999, 49, 241-7.	0.3	32
182	Carbachol stimulation of gastric acid secretion and its effects on the parietal cell. British Journal of Pharmacology, 1998, 124, 69-74.	2.7	20
183	Neuroendocrine differentiation in human gastric carcinoma. Cancer, 1998, 83, 435-444.	2.0	114
184	Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology, 1998, 114, 1113-1114.	0.6	27
185	Potentiating Hypergastrinemic Effect by the Peroxisome Proliferator Ciprofibrate and Omeprazole in the Rat. Scandinavian Journal of Gastroenterology, 1998, 33, 595-599.	0.6	11
186	Treatment with Proton Pump Inhibitors Induces Tolerance to Histamine-2 Receptor Antagonists inHelicobacter pylori-Negative Patients. Scandinavian Journal of Gastroenterology, 1998, 33, 1244-1248.	0.6	32
187	Maximal Gastric Acid Secretion in Man: A Concept That Needs Precision. Scandinavian Journal of Gastroenterology, 1998, 33, 1009-1015.	0.6	11
188	The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell. Journal of Molecular Endocrinology, 1998, 20, 111-117.	1.1	11
189	Hormones and carcinogenesis. Endocrine-Related Cancer, 1998, 5, 45-48.	1.6	7
190	Relationship of ECL cells and gastric neoplasia. Yale Journal of Biology and Medicine, 1998, 71, 325-35.	0.2	40
191	Neuroendocrine differentiation in human gastric carcinoma. Cancer, 1998, 83, 435-44.	2.0	33
192	Bombesin Inhibits Histamine Release from the Rat Oxyntic Mucosa by a Somatostatin-dependent Mechanism. Scandinavian Journal of Gastroenterology, 1997, 32, 427-432.	0.6	8
193	Release of Markers of Myocardial and Endothelial Injury Following Cold Cardioplegia Arrest in Pigs. Scandinavian Cardiovascular Journal, 1997, 31, 45-50.	0.4	7
194	Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound. Alimentary Pharmacology and Therapeutics, 1997, 11, 1013-1018.	1.9	70
195	Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?., 1997, 30, 1-6.		108
196	Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate., 1997, 31, 110-117.		54
197	Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?. , 1997, 30, 1.		3
198	Long-term effects of inhaled nicotine. Life Sciences, 1996, 58, 1339-1346.	2.0	105

#	Article	IF	CITATIONS
199	Non-proliferative capacity of endocrine cells of the human gastro-intestinal tract. The Histochemical Journal, 1996, 28, 397-398.	0.6	7
200	The fade of gastrin-stimulated gastric acid secretion in the rat is due to depletion of releasable mucosal histamine. Acta Physiologica Scandinavica, 1996, 157, 487-491.	2.3	5
201	Marked increase in gastric acid secretory capacity after omeprazole treatment Gut, 1996, 39, 649-653.	6.1	204
202	The peroxisome-proliferator ciprofibrate induces hypergastrinemia without raising gastric pH. Carcinogenesis, 1996, 17, 2153-2155.	1.3	21
203	Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4470-4475.	1.8	20
204	The gastrointestinal tract and the lungs. Similarities with particular emphasis on the neuroendocrine cells. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 1996, 13, 63-5.	0.2	3
205	Gastrin - Physiological and Pathophysiological Role: Clinical Consequences. Digestive Diseases, 1995, 13, 25-38.	0.8	35
206	Effect of the Histamine-2 Agonist Impromidine on Stem Cell Proliferation of Rat Oxyntic Mucosa. Scandinavian Journal of Gastroenterology, 1995, 30, 311-314.	0.6	9
207	Neuroendocrine cells in prostatic carcinoma. Human Pathology, 1995, 26, 1389.	1.1	5
208	Evaluation of the trophic effect of longterm treatment with the histamine H2 receptor antagonist loxtidine on rat oxyntic mucosa by differential counting of dispersed cells Gut, 1994, 35, 1547-1550.	6.1	15
209	Immunoassays for measurement of chromogranin a and pancreastatin-like immunoreactivity in humans: Correspondence in patients with neuroendocrine neoplasia. Neuropeptides, 1994, 26, 201-206.	0.9	46
210	Omeprazole Tolerability. Drug Safety, 1994, 11, 477-478.	1.4	0
211	The effect of tripotassium dicitrato bismuthate on the rat stomach. Alimentary Pharmacology and Therapeutics, 1994, 8, 425-431.	1.9	3
212	Do neuroendocrine cells, particularly the D-cell, play a role in the development of gastric stump cancer?. Cancer Detection and Prevention, 1994, 18, 431-6.	2.1	4
213	Classification of gastric carcinomas. Human Pathology, 1993, 24, 114-115.	1.1	3
214	The Enterochromaffin-Like (ECL) Cell Physiological and pathophysiological role. Acta Oncol \tilde{A}^3 gica, 1993, 32, 141-147.	0.8	25
215	Gastrin, the enterochromaffinlike cell, and gastric tumors. Gastroenterology, 1993, 105, 1264-1265.	0.6	9
216	Chromogranin a and Pancreastatin-Like Immunoreactivity in Serum of Gastrinoma Patients. Acta Oncol \tilde{A}^3 gica, 1993, 32, 161-165.	0.8	63

#	Article	IF	CITATIONS
217	Review article: the use of gastric acidâ€inhibitory drugsâ€"physiological and pathophysiological considerations. Alimentary Pharmacology and Therapeutics, 1993, 7, 589-596.	1.9	18
218	Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship Gut, 1992, 33, 1303-1306.	6.1	93
219	Biologic and Immunologic Gastrin Activity in Serum of Patients with Gastrinoma. Bioassay of Gastrin Activity in Serum. Scandinavian Journal of Gastroenterology, 1992, 27, 1039-1044.	0.6	2
220	Can NSAIDs Cause Acute Biliary Pain with Cholestasis?. Journal of Clinical Gastroenterology, 1992, 14, 328-330.	1.1	12
221	Rapid, high-yield isolation of human chromogranin A from chromaffin granules of pheochromocytomas. Neuropeptides, 1992, 22, 235-240.	0.9	21
222	Effects on the rat oxyntic mucosa of the histamine < sub>2 < /sub>â€antagonist loxtidine and the H < sup>+ < /sup>, K < sup>+ < /sup>â€ATPase inhibitor omepvazole. Alimentary Pharmacology and Therapeutics, 1992, 6, 335-349.	1.9	9
223	CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. American Journal of Physiology - Renal Physiology, 1991, 260, G925-G928.	1.6	49
224	Effect of the Histamine-1 Antagonist Astemizole Alone or with Omeprazole on Rat Gastric Mucosa. Scandinavian Journal of Gastroenterology, 1991, 26, 23-35.	0.6	45
225	Session 5: Trophic Effect of Histamine on the Stomach. Scandinavian Journal of Gastroenterology, 1991, 26, 137-142.	0.6	18
226	Session 4: Aspects of the Regulation of Gastric Histamine Release. Scandinavian Journal of Gastroenterology, 1991, 26, 108-112.	0.6	9
227	Session 5: Enterochromaffin-Like Tumour Cells in the Diffuse but not the Intestinal Type of Gastric Carcinomas. Scandinavian Journal of Gastroenterology, 1991, 26, 165-169.	0.6	25
228	Radioimmunoassay of Histamine. Scandinavian Journal of Gastroenterology, 1991, 26, 32-39.	0.6	30
229	24-Hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology, 1991, 101, 274.	0.6	1
230	Studies of Isolated Parietal and Enterochromaffin-Like Cells from the Rat. Scandinavian Journal of Gastroenterology, 1991, 26, 1295-1306.	0.6	47
231	Gastrin-histamine sequence in the regulation of gastric acid secretion Gut, 1991, 32, 698-701.	6.1	177
232	Session 3: The Gastrin Receptor Assay. Scandinavian Journal of Gastroenterology, 1991, 26, 62-69.	0.6	11
233	Rat gastric histamine release: A sensitive gastrin bioassay. Life Sciences, 1990, 46, 453-459.	2.0	34
234	Histamine and the Stomach. Scandinavian Journal of Gastroenterology, 1989, 24, 130-139.	0.6	39

#	Article	IF	Citations
235	Histamine release in the isolated vascularly perfused stomach of the rat: regulation by autoreceptors. British Journal of Pharmacology, 1989, 96, 557-562.	2.7	54
236	The Effect of Gastrin-Releasing Peptide on Acid Secretion and the Release of Gastrin, Somatostatin, and Histamine in the Totally Isolated, Vascularly Perfused Rat Stomach. Scandinavian Journal of Gastroenterology, 1989, 24, 9-15.	0.6	74
237	Histamine and Gastrin in Plasma of Patients with Upper Gastrointestinal Diseases. Digestion, 1989, 42, 121-127.	1.2	29
238	lonized calcium influences gastrin stimulated histamine release and acid secretion, but not histamine stimulated acid output in the totally isolated vascularly perfused rat stomach. Acta Physiologica Scandinavica, 1988, 134, 443-448.	2.3	14
239	The effect of somatostatin on baseline and stimulated acid secretion and vascular histamine release from the totally isolated vascularly perfused rat stomach. Regulatory Peptides, 1988, 20, 233-239.	1.9	50
240	Muscarinic M2 Stimulation Releases Histamine in the Totally Isolated, Vascularly Perfused Rat Stomach. Scandinavian Journal of Gastroenterology, 1988, 23, 1049-1056.	0.6	49
241	Do we need to listen to the Patient? the predictive Value of Symptoms. Scandinavian Journal of Gastroenterology, 1988, 23, 30-34.	0.6	30
242	The Effect of Misoprostol on Base-Line and Stimulated Acid Secretion and on Gastrin and Histamine Release in the Totally Isolated, Vascularly Perfused Rat Stomach. Scandinavian Journal of Gastroenterology, 1988, 23, 696-700.	0.6	21
243	Gastrin Produces an Immediate and Dose-Dependent Histamine Release Preceding Acid Secretion in the Totally Isolated, Vascularly Perfused Rat Stomach. Scandinavian Journal of Gastroenterology, 1987, 22, 803-808.	0.6	196
244	The Storage Time of Monoiodinated Gastrin Affects the Biological Activity and Binding to Rat Fundic Plasma Membranes Similarly, Whereas the Immunoreactivity Is Less Affected. Scandinavian Journal of Gastroenterology, 1987, 22, 390-396.	0.6	2
245	Gastric Acid Secretion in the Totally Isolated, Vascularly Perfused Rat Stomach: A Selective Muscarinic-1 Agent Does, Whereas Gastrin Does Not, Augment Maximal Histamine-Stimulated Acid Secretion. Scandinavian Journal of Gastroenterology, 1987, 22, 705-713.	0.6	63
246	Effect of Pentagastrin on Gastric Acid Secretion in the Totally Isolated Vascularly Perfused Rat Stomach Stimulated with the Phosphodiesterase Inhibitor Isobutyl Methylxanthine. Scandinavian Journal of Gastroenterology, 1986, 21, 577-584.	0.6	29
247	Gastrointestinal Regulatory Peptides: Radioimmunoassay and Biological Activity. Scandinavian Journal of Gastroenterology, 1986, 21, 1025-1028.	0.6	3
248	Bioassay of Gastrin, Using the Totally Isolated, Vascularly Perfused Rat Stomach: A Biomodel Sensitive to Gastrin in Physiological Concentrations. Scandinavian Journal of Gastroenterology, 1986, 21, 945-950.	0.6	13
249	The Effect of Pentagastrin on the Gastric Secretion by the Totally Isolated Vascularly Perfused Rat Stomach. Scandinavian Journal of Gastroenterology, 1986, 21, 379-384.	0.6	40
250	Binding and Degradation of ^{125 < /sup>I-Gastrin by Plasma Membranes from Homogenized Rat Gastric Mucosa. Scandinavian Journal of Gastroenterology, 1986, 21, 547-555.}	0.6	8
251	The Preparation of Bioactive125I-Gastrin, Using Iodo-gen as Oxidizing Agent, and the Use of This Tracer in Receptor Studies. Scandinavian Journal of Gastroenterology, 1985, 20, 569-576.	0.6	87
252	Gastritis, peptic ulcer disease, inflammatory bowel disease, and stomach and colon cancers â€" Are they all caused by viral infections?. Medical Hypotheses, 1981, 7, 1329-1338.	0.8	11

#	Article	IF	CITATIONS
253	Serum Group I Pepsinogens. Scandinavian Journal of Gastroenterology, 1981, 16, 449-451.	0.6	7
254	The Effect of a Test Meal on Serum Group I Pepsinogens (PG I) and Serum Gastrin in Persons with Normal Gastric H+Secretion and in Persons with Achlorhydria. Scandinavian Journal of Gastroenterology, 1980, 15, 267-271.	0.6	10
255	The Effect of Somatostatin on Serum Group I Pepsinogens (PG I), Serum Gastrin, and Gastric H+and Pepsin Secretion in Man. Scandinavian Journal of Gastroenterology, 1980, 15, 425-431.	0.6	12
256	Serum Group I Pepsinogens During Prolonged Infusion of Pentagastrin and Secretin in Man. Scandinavian Journal of Gastroenterology, 1979, 14, 761-768.	0.6	31
257	Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Endocrine Abstracts, 0, , .	0.0	1